Ghosh, Subrata
Bressler, Brian
Petkau, Jill
Thakkar, Roopal B.
Wang, Song
Skup, Martha
Chao, Jingdong
Panaccione, Remo
Schreiber, Stefan
Funding for this research was provided by:
AbbVie
Article History
Received: 26 January 2018
Accepted: 7 December 2018
First Online: 19 January 2019
Compliance with ethical standards
:
: S. Ghosh has served on ad hoc advisory boards of AbbVie, Merck, Shire, Pfizer, Receptos, Novo-Nordisk, Bristol-Myers Squibb, and Janssen. He has received honoraria for lecturing in educational events from AbbVie, Merck, Janssen, Takeda, and Shire and has received research support from AbbVie and Merck. B. Bressler is a consultant for AbbVie, Actavis, Jansen, Shire, Genentech, Takeda, Pendopharm, Celltrion; served on the Speaker’s Bureau for AbbVie, Jansen, Takeda, Shire, Ferring, Actavis; received research/educational support from AbbVie, Jansen, Millenium, Bristol-Myers Squibb, Amgen, GSK, Genentech, Celgene, AstraZeneca, RedHill Biopharma, Alvine, and BI, and has stock options from Qu Biologics. J Petkau has nothing to disclose. RB Thakkar and M Skup are employees of AbbVie and may hold stock. J Chao and S Wang were employees of AbbVie at the time of research and may own AbbVie stock. R Panaccione served as a consultant for AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Eisai, Ferring, Jansen, Merck, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Pfizer, Bristol-Myers Squibb, Warner Chilcott; served on the Speaker’s Bureau for AbbVie, AstraZeneca, Jansen, Schering-Plough, Shire, Centocor, Elan, Prometheus, and Warner Chilcott; served on advisory boards for AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Eisai, Ferring, Jansen, Merck, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Pfizer, Bristol-Myers Squibb, Warner Chilcott; and received research/educational support from AbbVie, Ferring, Jansen, Schering-Plough, Centocor, Millenium, Elan, Proctor and Gamble, and Bristol-Myers Squibb. S Schreiber served as study investigator and consultant for AbbVie and has participated in continuing medical education events supported by unrestricted educational grants from AbbVie. He has also served as a consultant and as a lecturer for Centocor/MSD, Schering-Plough, UCB, and Shire.
: The study protocol was approved by independent Medical Research Ethics Committees in agreement with local legal requirements in Canada and Germany. All patients provided written informed consent before participating in the study. Consenting patients were also asked to sign and date a form indicating that they were willing to have their HCP supply additional information about their condition and their current and previous CD treatment. To protect disclosure of patient identities, a unique identification number was assigned to each patient before collection of data; this identification number was used on both the patient and HCP questionnaires. No patient identifiable information was included in any of the information collected.